MMED
MiniMed (Nasdaq: MMED) announced that it expects to report financial results on Tuesday, September 1, 2026,...
Article Summary
BUY- MiniMed (Nasdaq: MMED) announced that it expects to report financial results on Tuesday, September 1, 2026, for its first quarter of fiscal year 2027, which ends on Friday, July 31,2026.
- MiniMed is a global leader in insulin delivery constantly advancing therapies that support people with diabetes in more than 80 countries, with full-stack integrated ecosystem including insulin delivery systems, CGMs, algorithms, and easy-to-use app experience.
- MMED pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier for over 40 years.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 20.6% | 20% | 70.0 ptsGood Upside (20.6%) - Target: $20.60 vs Current: $17.08 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -16.6% | 15% | 40.0 ptsMild Pullback (-16.6%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About MMED
- MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes.
- The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services.
- It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D.
- The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services.
- It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS.
- MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.
- MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.